Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Restructuring Costs (2016)

Ligand Pharmaceuticals (LGNDZ) has disclosed Restructuring Costs for 5 consecutive years, with $374000.0 as the latest value for Q2 2016.

  • Quarterly Restructuring Costs rose 71.56% to $374000.0 in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Jun 2016, up 1.01% year-over-year, with the annual reading at $1.0 million for FY2016, 1.18% up from the prior year.
  • Restructuring Costs hit $374000.0 in Q2 2016 for Ligand Pharmaceuticals, up from $244000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $562000.0 in Q4 2014 to a low of $44000.0 in Q2 2013.
  • Historically, Restructuring Costs has averaged $248058.8 across 5 years, with a median of $223000.0 in 2015.
  • Biggest five-year swings in Restructuring Costs: plummeted 89.37% in 2013 and later skyrocketed 209.09% in 2014.
  • Year by year, Restructuring Costs stood at $356000.0 in 2012, then plummeted by 43.54% to $201000.0 in 2013, then soared by 179.6% to $562000.0 in 2014, then tumbled by 58.36% to $234000.0 in 2015, then surged by 59.83% to $374000.0 in 2016.
  • Business Quant data shows Restructuring Costs for LGNDZ at $374000.0 in Q2 2016, $244000.0 in Q1 2016, and $234000.0 in Q4 2015.